检验医学
檢驗醫學
검험의학
LABORATORY MEDICINE
2015年
4期
349-352
,共4页
基因型%乙型肝炎病毒e抗原%乙型肝炎病毒%拉米夫定
基因型%乙型肝炎病毒e抗原%乙型肝炎病毒%拉米伕定
기인형%을형간염병독e항원%을형간염병독%랍미부정
Genotype%Hepatitis B eantigen%Hepatitis B virus%Lamivudine
目的:探讨绍兴地区拉米夫定治疗乙型肝炎病毒e抗原(HBeAg)阳性慢性乙型肝炎(CHB)患者乙型肝炎病毒( HBV)基因型的分布及其与抗病毒治疗疗效的关系。方法对122例HBeAg阳性CHB患者进行基因分型,分析接受拉米夫定抗病毒治疗1年后HBV基因型与HBV DNA、HBeAg、丙氨酸氨基转移酶( ALT)及HBV P基因变异的关系。结果122例CHB患者中,B基因型34例(27.87%),C基因型82例(67.21%),D基因型3例(2.45%),C/D混合基因型1例(0.82%),B/C混合基因型2例(1.64%)。 B基因型感染者的HBV DNA转阴率、HBeAg转阴率显著高于C基因型感染者(P均<0.01),HBV DNA水平显著低于C基因型感染者(P<0.05),ALT复常率高于C基因型感染者,但差异无统计学意义(P>0.05)。 B基因型感染者中临床表现以CHB轻度为主(44.12%),C基因型感染者临床表现以肝硬化失代偿期为主(30.49%)。 B基因型感染者发生基因变异0例,C基因型感染者发生变异4例,两者差异无统计学意义( P>0.05)。结论绍兴地区HBeAg阳性CHB患者HBV以C基因型为主,感染B型HBV的患者较感染C型HBV的患者对抗病毒治疗的应答为好,且临床表现较轻。
目的:探討紹興地區拉米伕定治療乙型肝炎病毒e抗原(HBeAg)暘性慢性乙型肝炎(CHB)患者乙型肝炎病毒( HBV)基因型的分佈及其與抗病毒治療療效的關繫。方法對122例HBeAg暘性CHB患者進行基因分型,分析接受拉米伕定抗病毒治療1年後HBV基因型與HBV DNA、HBeAg、丙氨痠氨基轉移酶( ALT)及HBV P基因變異的關繫。結果122例CHB患者中,B基因型34例(27.87%),C基因型82例(67.21%),D基因型3例(2.45%),C/D混閤基因型1例(0.82%),B/C混閤基因型2例(1.64%)。 B基因型感染者的HBV DNA轉陰率、HBeAg轉陰率顯著高于C基因型感染者(P均<0.01),HBV DNA水平顯著低于C基因型感染者(P<0.05),ALT複常率高于C基因型感染者,但差異無統計學意義(P>0.05)。 B基因型感染者中臨床錶現以CHB輕度為主(44.12%),C基因型感染者臨床錶現以肝硬化失代償期為主(30.49%)。 B基因型感染者髮生基因變異0例,C基因型感染者髮生變異4例,兩者差異無統計學意義( P>0.05)。結論紹興地區HBeAg暘性CHB患者HBV以C基因型為主,感染B型HBV的患者較感染C型HBV的患者對抗病毒治療的應答為好,且臨床錶現較輕。
목적:탐토소흥지구랍미부정치료을형간염병독e항원(HBeAg)양성만성을형간염(CHB)환자을형간염병독( HBV)기인형적분포급기여항병독치료료효적관계。방법대122례HBeAg양성CHB환자진행기인분형,분석접수랍미부정항병독치료1년후HBV기인형여HBV DNA、HBeAg、병안산안기전이매( ALT)급HBV P기인변이적관계。결과122례CHB환자중,B기인형34례(27.87%),C기인형82례(67.21%),D기인형3례(2.45%),C/D혼합기인형1례(0.82%),B/C혼합기인형2례(1.64%)。 B기인형감염자적HBV DNA전음솔、HBeAg전음솔현저고우C기인형감염자(P균<0.01),HBV DNA수평현저저우C기인형감염자(P<0.05),ALT복상솔고우C기인형감염자,단차이무통계학의의(P>0.05)。 B기인형감염자중림상표현이CHB경도위주(44.12%),C기인형감염자림상표현이간경화실대상기위주(30.49%)。 B기인형감염자발생기인변이0례,C기인형감염자발생변이4례,량자차이무통계학의의( P>0.05)。결론소흥지구HBeAg양성CHB환자HBV이C기인형위주,감염B형HBV적환자교감염C형HBV적환자대항병독치료적응답위호,차림상표현교경。
Objective To investigate the distribution of hepatitis B virus ( HBV) genotype of hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB) patients treated by lamivudine and its relationship with the efficiency of antiviral therapy .Methods A total of 122 HBeAg positive CHB patients were genotyped and received lamivudine treatment for 1 year, and the relationships of HBV genotype with HBV DNA , HBeAg, alanine aminotransferase ( ALT) and HBV P gene variation were analyzed .Results Among the 122 HBeAg positive CHB patients , there were 34 cases of B genotype (27.87%), 82 cases of C genotype (67.21%), 3 cases of D genotype (2.45%), 1 case of C /D mixed genotype (0.82%) and 2 cases of B /C mixed genotype (1.64%).The turning negative rates of HBV DNA and HBeAg in CHB patients with genotype B were higher significantly than those with genotype C (P<0.01), and the HBV DNA level was lower significantly than that with genotype C (P<0.05).The rate of normalization ALT was higher than that with genotype C, but had no statistical significance (P>0.05).Genotype B group were mainly patients with mild CHB (44.12 %), while genotype C group were mainly patients with uncompensated liver cirrhosis (30.49%). Genotype B infection group had no gene variation , there were 4 cases of variation in genotype C infection group , and there was no statistical significance(P>0.05).Conclusions HBV genotype C of HBeAg positive CHB patients is the major genotype in Shaoxing .HBV patients with geotype B infection have better response for antiviral therapy than those with genotype C infection , and the clinical manifestation is light .